Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

Inclusion Criteria: * Histologically confirmed metastatic adenocarcinoma of the lung * Patients must have received and completed first line therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1 * No external beam radiation therapy within 2 weeks of first vaccine administration * No stereotactic radiation therapy within 3 days of first vaccine * No targeted therapy within 2 weeks of first vaccine administration * No immunomodulatory therapy within 2 weeks of first vaccine administration * No chemotherapy within 4 weeks of first vaccine administration * During Screening period, no steroid therapy within 4 weeks of first vaccine administration * Patient's written informed consent * Adequate organ function (measured within a week of beginning treatment): * White blood count (WBC) \> 3,000/mm³ and absolute neutrophil count (ANC) \>/= 1500/mm³ * Platelets \> 100,000/mm³ * Hematocrit \> 25% * Bilirubin \< 2.0 mg/dL * Creatinine \< 2.0 mg/dL, or creatinine clearance \> 60 mL/min * Patients will be tested for HLA-A0201 as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen; however this result will not be an inclusion criterion. * Measurable metastatic tumor as defined by standard Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Lesions must be accurately measured in at least one dimension with the longest diameter ≥20 mm. With spiral computed tomography (CT) scan, lesion must be ≥10 mm in at least one dimension. Exclusion Criteria: * Symptomatic brain metastasis or Uncontrolled central nervous system (CNS) metastasis will not be permitted. * Any acute medical problems requiring active intervention * Current corticosteroid (other than replacement doses in patients who are hypo-adrenal) or other immunosuppressive therapy * Any other pre-existing immunodeficiency condition (including known human immunodeficiency virus \[HIV\] infection) * Any known pre-existing autoimmune disorder * History of a second malignancy within the previous 2 years (except non-melanoma skin cancer and cervical in-situ) * Patients who have had major surgery without full recovery or major surgery within three weeks of the start of vaccine treatment * Pregnant or lactating women: Patients in reproductive age must agree to use contraceptive methods for the duration of the study (\*A pregnancy test will be obtained before treatment). * Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4 * Patients with other significant diseases or disorders that, in the Investigator's opinion, would exclude them from the study. * Patients who at the discretion of the investigator are deemed to have rapidly progressive disease